



Pathophysiology and Treatment of Gallbladder Cancer

Guest Editors:

Dr. Philip De Reuver

Department of Surgery, Radboud
University Medical Centre, 6500
HB Nijmegen, The Netherlands

Dr. Chella van der Post

Department of Pathology,
Radboud University Medical
Centre, 6500 HB Nijmegen, The
Netherlands

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editors


Dear Colleagues,

Gallbladder cancer (GBC) is a rare and highly lethal neoplasm of the biliary tract. GBC demonstrates significant geographic, age-, gender-, and ethnicity-related differences in incidence, but the cause of GBC and its pathophysiology is not well understood. (Epi)Genetics or environmental factors may play an essential role in the development of GBC. Other possible risk factors include cholelithiasis, obesity, gallbladder polyps, chronic infections, and an abnormal pancreaticobiliary duct junction. However, most patients with GBC do not have any of the known risk factors apart from age. It could be hypothesized that different causes of gallbladder cancer also imply different treatment strategies.

This Special Issue will focus on the current insights into the pathophysiology, treatment and predictive factors for survival of gallbladder cancer in different geographic area's. This issue aims to improve our understanding in the development of GBC. We look forward to your contributions.

Dr. Philip De Reuver
Dr. Chella van der Post
Guest Editors





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI